Inhibikase Therapeutics Inc
IKT
NASDAQ
Biotechnology
$2.41
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $336.28M
Volume 227.9K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-60.64M
TTM
-46.1%
YoY
Operating Cash Flow
$-42.61M
TTM
-114.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.9 | 5.6 | 6.8 | 7.4 | 7.7 |
Other Operating Expenses | -0.4 | -0.5 | 0.6 | -0.4 | 0.0 |
Total Operating Expenses | 10.8 | 12.8 | 13.8 | 17.8 | 21.1 |
Operating Income | -10.8 | -12.8 | -13.8 | -17.8 | -21.1 |
EBITDA | -10.8 | -12.7 | -13.8 | -17.8 | -21.1 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.9 | 0.8 | 1.0 | 1.5 | 1.5 |
Income Before Income Taxes | -9.9 | -11.9 | -12.7 | -16.4 | -19.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -9.9 | -11.9 | -12.7 | -16.4 | -19.6 |
Consolidated Net Income / Loss | -9.9 | -11.9 | -12.7 | -16.4 | -19.6 |
Net Income Attributable to Common Shareholders | -9.9 | -11.9 | -12.7 | -16.4 | -19.6 |
Basic EPS | -$0.11 | -$0.13 | -$0.10 | -$0.10 | -$0.11 |
Diluted EPS | -$0.11 | -$0.13 | -$0.10 | -$0.10 | -$0.11 |
Basic Shares Outstanding | 90.0M | 90.1M | 123.6M | 172.3M | 174.6M |
Diluted Shares Outstanding | 90.0M | 90.1M | 123.6M | 172.3M | 174.6M |